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Abstract
The Cubicin Outcomes Registry and Experience (CORE) is an ongoing, retrospective, post-marketing database of daptomycin use in the
USA. Although non-comparative, CORE offers insight into real-life clinical experience with daptomycin in various Gram-positive infec-
tions and speciﬁc patient types. Analyses of daptomycin treatment outcomes using the CORE database revealed that treatment with
daptomycin has resulted in high rates of clinical success for a variety of Gram-positive infections, including indicated infections such as
complicated skin and soft tissue infections, Staphylococcus aureus bacteraemia and right-sided infective endocarditis, and non-indicated
infections such as osteomyelitis. Treatment outcomes did not differ signiﬁcantly according to the causative pathogen for any of the
analyses performed and were not inﬂuenced by the vancomycin MIC. Patients frequently received therapy with alternative antibiotics
prior to treatment with daptomycin, particularly those patients with more serious infections. However, similar treatment outcomes
were observed when daptomycin was used as ﬁrst-line therapy or as salvage therapy, demonstrating the effectiveness of daptomycin in
the treatment of these patients.
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Introduction
Over the past decade, several new antibiotics have been
approved for the treatment of resistant Gram-positive infec-
tions, including quinupristin–dalfopristin, approved in the
USA and the EU in 1999 [1,2]; linezolid, approved in the
USA in 2000 and in the EU in 2001 [3,4]; tigecycline,
approved in the USA in 2005 and in the EU in 2006 [5,6];
and daptomycin, approved in the USA in 2003 and in the EU
in 2006 [7,8]. Although the availability of more antibiotics
can provide clinicians with various treatment options, they
can also potentially complicate medical decision-making,
particularly in cases where published clinical data are sparse.
When selecting the most appropriate antimicrobial ther-
apy, clinicians are frequently forced to extrapolate antibiotic
properties displayed in vitro or in animal models to the indi-
vidual patient’s circumstances and speciﬁc pathogen-related
factors. For example, clinicians may favour the use of antibi-
otics with bactericidal activity in vitro when dealing with bac-
teraemia, endocarditis and meningitis, because this property
has been demonstrated to be important in the treatment of
these serious infections [9], even when clinical experience
with these agents is limited. The adverse event proﬁle of
certain antibiotics may steer clinicians away from using them
in some patient populations. For example, clinicians may
avoid aminoglycosides and high-dose vancomycin therapy in
non-dialysis patients with renal failure, because these agents
are associated with a high incidence of nephrotoxicity [10].
Host factors that inﬂuence antimicrobial selection include
the presence of comorbidities, such as immunosuppression,
neutropenia, renal failure and prior antibiotic exposure, the
severity of illness, and the epidemiological setting of infection
onset. The site of infection will have an impact, because of
the varying abilities of individual antibiotics to penetrate or
retain activity in certain in vivo compartments.
Microbiological considerations are becoming increasingly
important in the current climate of increasing antimicrobial
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resistance. A recent concern is the upwards shift in vanco-
mycin MIC for Staphylococcus aureus strains over time, the
‘MIC creep’, which has been demonstrated in a number of
single-centre studies [11–13] and was reported recently in a
study of three hospitals in the Detroit area of the USA over
a 22-year period [14]. The adverse impacts of these
increases in vancomycin MIC on various clinical parameters,
such as efﬁcacy [15–17], mortality [18], duration of hospital
stay and overall cost of therapy [19], have been demon-
strated. The phenomenon of MIC creep is not limited to
vancomycin, and has been demonstrated in one study for
both linezolid and oxacillin [11]; however, the clinical signiﬁ-
cance of this is less well documented. One study showed
that a linezolid MIC of 4 mg/L, the upper limit of susceptibil-
ity, was associated with inferior microbiological eradication
of methicillin-resistant S. aureus infections when compared
with those where the organism had a linezolid MIC of
£2 mg/L [20]. Although rare, glycopeptide-intermediate
S. aureus strains with vancomycin MICs of 4–8 mg/L may be
of particular concern, as these strains show raised MICs
in vitro (as compared with vancomycin-susceptible strains) for
many of the newer classes of Gram-positive agents, such as
the lipoglycopeptides [21–23] and daptomycin [24], although
the clinical relevance of this is unknown.
The Cubicin Outcome Registry and Experience (CORE) is
an ongoing, retrospective, post-marketing database of
infection outcomes with daptomycin therapy in the USA.
Daptomycin was approved initially for the treatment of
complicated skin and soft tissue infections (cSSTIs) in 2003,
with subsequent approval being given in 2006 for S. aureus
bacteraemia (SAB) and right-sided infective endocarditis (RIE)
in the USA [7], and in 2007 for RIE caused by S. aureus and
SAB associated with RIE or cSSTIs in the EU [8]. Analyses
of the data from CORE have been, and continue to be,
performed for numerous types of Gram-positive infections
and in various patient groups, by calendar year. By reviewing
the published clinical outcomes with daptomycin, as reported
to the CORE database during 2004 (n = 1160) and 2005
(n = 1172) [25], this article offers insights into the real-life
experience of daptomycin therapy in various infections and
speciﬁc patient types.
An Introduction to CORE
The primary objective of CORE is to evaluate retrospectively
the clinical outcomes of patients treated with daptomycin,
with additional objectives that include the characterization
and description of the patient populations being treated with
daptomycin, as well as the types of infections and pathogens
[26]. Patients were eligible for inclusion if they have received
at least one dose of daptomycin, but not as part of a con-
trolled clinical trial, and have initiated and completed dapto-
mycin treatment within the calendar year [26]. Data on
patient demographics, microbiological characteristics, antibi-
otic therapy and efﬁcacy and safety outcomes are extracted
from standardized case report forms that have been com-
pleted by trained investigators.
Standard deﬁnitions are used to classify clinical outcomes
at the end of therapy as success (the sum of cure plus
improvement) or failure. Cure is deﬁned as resolution of
clinical signs and symptoms and/or no additional antibiotic
therapy being considered necessary, or as infection being
cleared with a negative culture reported at the end of dapto-
mycin therapy. Patients are deemed to have improved if
there is partial resolution of clinical signs and symptoms and/
or additional antibiotic therapy is considered necessary at
the end of daptomycin therapy (e.g. a patient who is
switched to oral antibiotic therapy at the time of hospital
discharge). Patients with an inadequate response to daptomy-
cin therapy, the development of resistance, worsening or
new/recurrent signs and symptoms, the need for a change in
antibiotic therapy or with a positive culture reported at the
end of therapy [26] are classiﬁed as failures. A non-evaluable
outcome is assigned when investigators are unable to deter-
mine response at the end of daptomycin therapy because the
records do not contain adequate information [26].
A Summary of the Results of CORE
Clinical experience with daptomycin by infection type
The types of infections treated with daptomycin in 2004 and
2005 are shown in Fig. 1 [25]; the microbiological character-
istics and antibiotic therapy for these infections in 2004 are
summarized in Table 1. Outcomes for 750 patients (522
patients with skin infections, 126 patients with bacteraemia,
35 patients with infective endocarditis (IE) and 67 patients
with osteomyelitis) treated with daptomycin in 2004 and 565
patients (478 patients with skin infections, 61 patients with
non-catheter-related bacteraemia and 26 patients with IE)
treated in 2005 are reviewed [27–34].
Skin infections. Surgical site infections constituted the most
common type of cSSTI treated in both 2004 [27] and 2005
[31], followed by infected wounds and major abscesses. The
median daptomycin dose and treatment duration for these
infections were in line with the treatment recommendation
for cSSTIs (4 mg/kg/day for 7–14 days) [8]. In 2004, the
overall rate of treatment success was 97% (Table 2), ranging
12 Clinical Microbiology and Infection, Volume 15, Supplement 6, December 2009 CMI
ª2009 The Author
Journal Compilation ª2009 European Society of Clinical Microbiology and Infectious Diseases, CMI, 15 (Suppl. 6), 11–16
from 88% for infected ulcers to 100% for infected diabetic
ulcers and mixed cSSTIs, with a similar overall rate of treat-
ment success being reported for 2005 (94.4%). Success rates
were similar for uncomplicated skin and soft tissue infections
and cSSTIs in both years; no differences in treatment
outcomes were observed when results were stratiﬁed by
primary pathogen. The rates of treatment success reported
for these infections in CORE are higher than those reported
for the phase III trials in cSSTIs (83.4% in the clinically evalu-
able population for daptomycin vs. 84.2% for comparator-
treated patients) [35].
Bloodstream infections. More than half of the bloodstream
infections reported in the 2004 CORE database were cathe-
ter-related (56%) [28]. The median initial dose of daptomycin
was 4 mg/kg/day (Table 1), which is lower than the currently
recommended dose of 6 mg/kg/day for this indication [8].
Although current clinical experience discourages use of the
4 mg/kg/day dose for the treatment of bacteraemia, the use
of this lower dose reﬂects the lack of clinical trial data avail-
able for daptomycin dosing in the treatment of bacteraemia
prior to 2006. Overall treatment success with daptomycin
for bacteraemia was 89%, and was similar for catheter-
related and non-catheter-related infections (Table 2). No
signiﬁcant differences in outcome were found when analysed
according to primary cultured pathogen, with success rates
ranging from 88% for methicillin-resistant S. aureus to 100%
for methicillin-susceptible S. aureus and Streptococcus species.
Similarly, the stratiﬁcation of outcomes according to baseline
creatinine clearance (CrCl) or concomitant antimicrobial
therapy did not reveal any differences in clinical success rates
(p =0.37 and p =0.55, respectively). An overall clinical
success rate of 79% was reported in a 2005 analysis of
non-catheter-related bloodstream infections [32], which is
consistent with the clinical success rate of 77% reported for
a retrospective study of 31 bacteraemic patients treated with
daptomycin [36].
IE. The median initial daptomycin dose of 6 mg/kg/day admin-
istered in 2004 (Table 1) and 2005 is consistent with current
recommendations [8,33]. Clinical outcomes were available for
35 of 49 patients treated for IE during 2004 and for 26 of 38
IE patients treated in 2005 [33]. These patient groups included
28 and 17 patients with left-sided (or both left-sided and right-
sided) IE and seven and nine patients with RIE in 2004 and
2005, respectively [29,33]. S. aureus was isolated from 59% of
IE patients in 2004, and from 63% in 2005, predominating in
both left-sided and right-sided infection in both years. The
FIG. 1. Infection types of the 2332 patients (includes non-evaluable
patients) treated with daptomycin in 2004 and 2005 [25]. cSSTI,
complicated skin and soft tissue infection; IE, infective endocarditis;
uSSTI, uncomplicated skin and soft tissue infection. *Other: foreign-
body infections, septic arthritis, urinary tract infections, central
nervous system infections, and necrotizing infections.
TABLE 1. Summary of the microbiological characteristics of and antibiotic therapy for patients treated with daptomycin in
2004 [27–30,34]
Infection type (no. of patients)
Skin (522)
uSSTI (188) cSSTI (334) Bacteraemia (126) Infective endocarditis (49)a Osteomyelitis (67)b
Most frequent pathogens (%) MRSA (82)
MSSA (11)
MRSA (57)
CoNS (13)
MRSA (33)
VRE, CoNS (30)
MRSA (49)
Enterococcus faecalis (12.2)c
MRSA (45)
MSSA (21)
Median initial dose (range) (mg/kg/day) 4 (2.1–9) 4 (2.3–12) 4 (2.5–9.2) 6 (4–7) 5.6 (3.2–7.5)
Median treatment duration (range) (days) 12 (1–148) 12.5 (1–66) 27 (5–62) 35 (3–546)
Rate of prior antibiotic therapy (%) 59 71 86 88 90
Rate of concomitant antibiotic therapy (%) 42 69 65 48
CoNS, coagulase-negative staphylococci; cSSTI, complicated skin and soft tissue infection; MRSA, methicillin-resistant Staphylococcus aureus; MSSA, methicillin-susceptible S. aur-
eus; uSSTI, uncomplicated skin and soft tissue infection; VRE, vancomycin-resistant enterococci.
aOnly 35 of these patients were clinically evaluable for treatment success.
bAt follow-up evaluation; only 62 of these patients were clinically evaluable for treatment success.
cVancomycin-susceptible.
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overall treatment success rates for clinically evaluable patients
were 89% in 2004 (Table 2) and 77% in 2005 [33]. Although
not directly comparable, these rates of clinical success are
similar to the results of the phase III clinical trial in SAB and IE
when those failures not related to clinical failure, microbiologi-
cal failure or death are excluded [37].
Osteomyelitis. The 2004 CORE analysis of daptomycin out-
comes in osteomyelitis is the only CORE analysis to report
outcomes from a follow-up visit (median 76 days after the
end of therapy) [30]. In the subset of 67 patients assessed at
follow-up, concurrent bacteraemia was diagnosed in 24% of
patients and orthopaedic devices were present in 25% of
patients. The overall clinical success rate at the follow-up
visit, for the 62 clinically evaluable patients, was 89%
(Table 2), with subgroup analysis showing high rates of clini-
cal success in those patients with concurrent bacteraemia
(88%) or with orthopaedic devices (100%). Surgical debride-
ment, performed in 60% of patients, had a considerable
impact on outcomes, as shown by the signiﬁcant decrease in
the failure rate from 24% to 5% (p =0.045) if surgery was
performed. The appropriate dose of daptomycin for osteo-
myelitis is unknown, but is highly likely to be >6 mg/kg/day.
This study revealed a higher failure rate in patients who
received 4 mg/kg/day or less (29%) than in those receiving
more than 4 mg/kg/day (4%) (p =0.013). Clinical success
rates according to the primary infecting pathogen were not
signiﬁcantly different, ranging from 75% for enterococci to
100% for streptococci and coagulase-negative staphylococci.
Outcomes of daptomycin treatment in different patient
populations
A patient’s degree of renal function, the prior administration
of alternative antibiotic therapy and changes in the suscepti-
bility proﬁle of infecting pathogens all have potential impacts
on treatment outcomes.
Clinical outcomes of 598 patients in 2004 with normal kid-
ney function or mild-to-moderate renal impairment
(CrCl ‡30 mL/min) were compared with those of 172 patients
who had severe renal impairment (CrCl <30 mL/min), but did
not require renal replacement therapy [38]. The two
patient groups had similar clinical success rates: 95% for
patients with CrCl ‡30 mL/min and 96% for patients with
CrCl <30 mL/min. This is in contrast to the ﬁndings for 2005,
which revealed that patients with CrCl <30 mL/min had lower
success rates than those with CrCl ‡30 mL/min (82% vs. 94%,
respectively; p <0.0001). This difference remained signiﬁcant
even after controlling for patient differences in a multivariate
analysis [39]. Other analyses of outcomes in patients receiving
renal replacement therapy, and in those patients undergoing
haemodialysis, have demonstrated that daptomycin is being
used in these patients to treat a wide range of infection types,
including bacteraemia, skin and soft tissue infections, foreign-
body infections, endocarditis and osteomyelitis, with high rates
of clinical success (88% for patients undergoing general renal
replacement therapy, and 85% for patients undergoing
haemodialysis) [40,41].
In order to assess the impact of prior antibiotic therapy on
daptomycin outcomes, data from 2005 for patients who
received daptomycin as ﬁrst-line therapy (n = 212) and those
who received daptomycin subsequent to treatment with
alternative antimicrobial agents (n = 735) were compared
[42]. No signiﬁcant difference in treatment outcomes between
these two patient groups was observed; the clinical success
rates were 95% and 92% for ﬁrst-line therapy and subsequent
daptomycin therapy, respectively. However, further analysis of
outcomes in these patients revealed that clinical success was
statistically lower for those patients who had failed on vanco-
mycin therapy (86%) than for those patients receiving ﬁrst-line
daptomycin therapy (p <0.01). This difference is likely to be
accounted for by signiﬁcant differences in co-morbidities and
infection types between the two patient groups; patients who
had failed vancomycin therapy were older and had higher rates
of chronic kidney disease.
Some reports have suggested a relationship between
vancomycin MICs and daptomycin MICs [43–45]. However, a
deﬁnitive mechanism for this has not been established, and
the clinical relevance of this relationship is not fully esta-
blished [46]. In an analysis of the CORE data that assessed
the impact of increased vancomycin MIC on daptomycin
treatment efﬁcacy, there were no signiﬁcant differences
in daptomycin treatment success after stratiﬁcation by
TABLE 2. Clinical success rates (%) for clinically evaluable patients treated with daptomycin in 2004 [27–30]
Skin infection Bacteraemia Infective endocarditis Osteomyelitisa
Overall (n = 522) 97 Overall (n = 126) 89 Overall (n = 35) 89 Overall (n = 62) 89
uSSTI (n = 188) 98 Catheter-related (n = 71) 89 Left-sided (n = 28) 89 Bacteraemic (n = 16) 88
cSSTI (n = 334) 96 Non-catheter-related (n = 55) 89 Right-sided (n = 7) 86 Orthopaedic device (n = 14) 100
cSSTI, complicated skin and soft tissue infection; uSSTI, uncomplicated skin and soft tissue infection.
aAssessment at follow-up evaluation.
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vancomycin MIC within the susceptible range [47]. A clinical
success rate of 94% was observed in patients where S. aureus
isolates had a vancomycin MIC of £1 mg/L (n = 401), as
compared with 92% when isolates had a vancomycin MIC of
>1 mg/L (n = 75; p not signiﬁcant).
Summary
The results of clinical trials are not necessarily an accurate
representation of clinical practice, owing, in part, to the strict
inclusion and exclusion criteria of these trials, as well as
deﬁnitions for success, which may result in the assignment of
clinical failure as a result of something other than lack of
efﬁcacy. The value of the CORE database is that it reﬂects
the real-life use of daptomycin in clinical practice in a way that
randomized clinical trials do not, despite having its own inher-
ent limitations, such as the measurement of effectiveness
being based on the subjective assessment of investigators
[26].
Analyses of daptomycin treatment outcomes using the
CORE database revealed that treatment with daptomycin
has resulted in high rates of clinical success for a variety of
Gram-positive infections, including indicated infections such
as cSSTIs, bacteraemia and IE, and non-indicated infections
such as osteomyelitis. Treatment outcomes did not differ
signiﬁcantly according to the causative pathogen for any of
the analyses performed and were not inﬂuenced by the
vancomycin MIC for vancomycin-susceptible S. aureus. Renal
function has had an inconsistent effect on clinical outcomes
with daptomycin therapy. Patients frequently received
therapy with alternative antibiotics prior to treatment with
daptomycin, particularly those patients with more serious
infections. However, similar treatment outcomes were
observed when daptomycin was used as ﬁrst-line therapy or
as salvage therapy, demonstrating the effectiveness of dapto-
mycin in the treatment of these patients. Therefore, experi-
ence with daptomycin suggests that it is an effective
antimicrobial agent for the treatment of various Gram-posi-
tive infections across a range of patient populations.
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